These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38286304)

  • 1. Is schedule IV suvorexant an appropriate reference drug of abuse to use in preclinical abuse liability testing in the rat?
    Teuns GBA; Tessari M
    Regul Toxicol Pharmacol; 2024 Mar; 148():105570. PubMed ID: 38286304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats.
    Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M
    J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
    Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
    J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
    Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR
    Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats.
    Simmons SJ; Martorana R; Philogene-Khalid H; Tran FH; Gentile TA; Xu X; Su S; Rawls SM; Muschamp JW
    Psychopharmacology (Berl); 2017 Nov; 234(21):3207-3215. PubMed ID: 28786030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
    Landry I; Hall N; Aluri J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):365-373. PubMed ID: 35749758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.
    Asakura S; Shiotani M; Gauvin DV; Fujiwara A; Ueno T; Bower N; Beuckmann CT; Moline M
    Regul Toxicol Pharmacol; 2021 Dec; 127():105053. PubMed ID: 34619288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
    Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
    J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia.
    Chavan P; Chikahisa S; Shiuchi T; Shimizu N; Dalanon J; Okura K; Séi H; Matsuka Y
    Brain Res Bull; 2022 Oct; 188():39-46. PubMed ID: 35868501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.